` PBM (Psyence Biomedical Ltd) vs S&P 500 Comparison - Alpha Spread

P
PBM
vs
S&P 500

Over the past 12 months, PBM has underperformed S&P 500, delivering a return of -95% compared to the S&P 500's +14% growth.

Stocks Performance
PBM vs S&P 500

Loading
PBM
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
PBM vs S&P 500

Loading
PBM
S&P 500
Difference
www.alphaspread.com

Performance By Year
PBM vs S&P 500

Loading
PBM
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Psyence Biomedical Ltd vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Psyence Biomedical Ltd
Glance View

Market Cap
1.9m USD
Industry
N/A

Psyence Biomedical Ltd is a CA-based company operating in industry. The company is headquartered in Toronto, Ontario. The company went IPO on 2021-12-10. Psyence Biomedical Ltd is a Canada-based company, which develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The firm has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.

PBM Intrinsic Value
Not Available
P
Back to Top